Ginsenosides have offered a wide array of beneficial roles in the pharmacological regulation of hepatic metabolic syndromes, including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), and obesity. Of the numerous ginsenosides, Rg3 has been widely investigated, but there have been few studies of gypenosides (Gyp). Particularly, no study on Gyp LXXV has been reported to date. Here, to firstly explore the pharmacological effects of Gyp LXXV against NASH and the related mechanism, methionine- and choline-deficient (MCD) diet-induced NASH mice and hepatic cells (stellate cells, hepatic macrophages, and hepatocytes) were selected. Gyp LXXV exhibited markedly alleviated MCD diet-induced hepatic injury, inflammation, and fibrosis by down-regulating hepatic fibrosis markers such as α-smooth muscle actin(α-SMA), collagen1, transforming growth factors-β (TGF-β1), tumor necrosis factor-α (TNF-α), MCP-1, interleukin (IL)-1β, nuclear factor κB (NFκB), and GRP78. Remarkably, histopathological studies confirmed that 15 mg/kg of Gyp LXXV administration to MCD diet-induced mice led to effective prevention of liver injury, lipid accumulation, and activation of hepatic macrophages, indicating that Gyp LXXV might be a potential anti-NASH drug.

中文翻译：

---

Gypenoside LXXV 对非酒精性脂肪性肝炎 (NASH) 的药效

人参皂苷在肝脏代谢综合征的药理调节中发挥了广泛的有益作用，包括非酒精性脂肪性肝炎 (NASH)、非酒精性脂肪性肝病 (NAFLD) 和肥胖症。在众多的人参皂苷中，Rg3 已被广泛研究，但很少有人对绞股蓝皂苷 (Gyp) 进行研究。特别是，迄今为止还没有关于 Gyp LXXV 的研究报告。在这里，为了首先探索 Gyp LXXV 对 NASH 的药理作用及其相关机制，选择了蛋氨酸和胆碱缺乏 (MCD) 饮食诱导的 NASH 小鼠和肝细胞（星状细胞、肝巨噬细胞和肝细胞）。Gyp LXXV 通过下调肝纤维化标志物，如 α-平滑肌肌动蛋白 (α-SMA)、胶原蛋白1、转化生长因子-β (TGF-β1)、肿瘤坏死因子-α (TNF-α)、MCP-1、白细胞介素 (IL)-1β、核因子 κB (NFκB) 和 GRP78。值得注意的是，组织病理学研究证实，给予 MCD 饮食诱导的小鼠 15 mg/kg Gyp LXXV 可有效预防肝损伤、脂质积累和肝巨噬细胞的激活，表明 Gyp LXXV 可能是一种潜在的抗 NASH 药物。